Part,  Chapter, Paragraph

 1   II,     5.  3.  7|         drugs.~· With respect to pricing, there are two questions
 2   II,     5.  3.  7|      from a national to a global pricing structure and this will
 3   II,     5.  5.  3|       patients on issues such as pricing and reimbursement matters.
 4  III,    10.  2.  1|   increase in average scores for pricing, health warnings and tobacco
 5  III,    10.  2.  1|          such as food labelling, pricing and availability. Pricing
 6  III,    10.  2.  1|        pricing and availability. Pricing strategies can influence
 7  III,    10.  2.  1| interventions (e.g. taxation and pricing policies) have been successfully
 8  III,    10.  2.  1|         for tobacco and alcohol; pricing policies for food or its
 9  III,    10.  4.  1|         emission ceilings; and~· Pricing in energy and fuels.~ ~ ~ ~
10   IV,    11.  3.  2|      about market authorization, pricing and reimbursement (i.e.
11   IV,    11.  3.  2|         Medicines Agency (EMEA), pricing and reimbursement policies
12   IV,    11.  3.  2|        comparisons and reference pricing. Price fixing is based on
13   IV,    11.  3.  2|          and the UK.~ ~Reference pricing, a form of indirect price
14   IV,    11.  3.  2|      Mossialos, 2004). Reference pricing is also widely used in central
15   IV,    11.  3.  2|          and Slovakia. Reference pricing can also be linked to reimbursement
16   IV,    11.  3.  2|        UK, where there is a free pricing at the time of launch, but
17   IV,    11.  3.  2|     considered to some extent in pricing. This practice is either
18   IV,    11.  3.  2|      becoming more important for pricing in France).~ ~Other possible
19   IV,    11.  3.  2|        France).~ ~Other possible pricing mechanisms to contain costs
20   IV,    11.  3.  2|   however, is the integration of pricing and reimbursement activities,
21   IV,    11.  3.  2|         in the form of reference pricing (as mentioned above). Policies
22   IV,    11.  6.  4|     Belgium, the Pharmaceuticals Pricing Boards in Finland, Norway,
23   IV,    11.  6.  4|      Norway, and Sweden, and the Pricing and Reimbursement Committee
24   IV,    11.  6.  4|    involved in reimbursement and pricing decisions often differ from
25   IV,    11.  6.  5|           2006): "Pharmaceutical pricing in Europe: Weighing up the
26   IV,    12.  1    | practices, market authorization, pricing, and reimbursement, was
27   IV,    12.  1    |         Medicines Agency (EMEA), pricing and reimbursement policies
28   IV,    12. 10    |          A progressive system of pricing water consumption is applied